Cargando…
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
INTRODUCTION: Theoretical risks of biologic agents remain under study. OBJECTIVE: The aim of this study was to integrate 1-year safety data from 12 ustekinumab registrational trials. METHODS: Patients had moderate-to-severe plaque psoriasis, active psoriatic arthritis (PsA) (± methotrexate), or mode...
Autores principales: | Ghosh, Subrata, Gensler, Lianne S., Yang, Zijiang, Gasink, Chris, Chakravarty, Soumya D., Farahi, Kamyar, Ramachandran, Paraneedharan, Ott, Elyssa, Strober, Bruce E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520311/ https://www.ncbi.nlm.nih.gov/pubmed/30739254 http://dx.doi.org/10.1007/s40264-019-00797-3 |
Ejemplares similares
-
Correction to: Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
por: Ghosh, Subrata, et al.
Publicado: (2019) -
Ustekinumab in the Treatment of Psoriasis and Psoriatic Arthritis
por: Savage, Laura J., et al.
Publicado: (2015) -
Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn’s Disease and 2 Years in Ulcerative Colitis
por: Abraham, Bincy P, et al.
Publicado: (2022) -
Ustekinumab-induced amelioration of both palmoplantar psoriasis and psoriatic glossitis
por: Tonini, Annalisa, et al.
Publicado: (2019) -
Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
por: Helliwell, Philip S, et al.
Publicado: (2020)